EUR/USD likely to find a peak near 1.25: UBS
On Monday, Cantor Fitzgerald analysts reiterated their Overweight rating and maintained a $9.00 price target on TriSalus Life Sciences, Inc. (NASDAQ:TLSI), despite the stock’s recent 10% decline over the past week. According to InvestingPro data, analyst consensus remains strongly bullish with targets ranging from $9 to $16, suggesting significant upside potential. This decision follows the announcement of a leadership change within the company.
TriSalus Life Sciences revealed the appointment of David B. Patience as the new Chief Financial Officer, effective July 1, 2025. Patience previously held the position of CFO at Accelerate Diagnostics (OTC:AXDXQ). In the meantime, Dan Giordano, the company’s Vice President of Finance, will assume the role of Acting CFO. InvestingPro analysis shows the company maintains a healthy current ratio of 2.14, though it’s currently burning through cash with negative free cash flow.
The outgoing CFO, James Young, stepped down from his position for personal reasons, effective last Friday. The company expressed well wishes for Young and anticipation of working with Patience in his new role.
Cantor Fitzgerald’s analysts did not alter their outlook on TriSalus Life Sciences following the CFO transition, maintaining confidence in the company’s future prospects with the reiterated stock rating and price target.
In other recent news, TriSalus Life Sciences reported a strong first quarter for 2025, with revenues reaching $9.2 million, marking a 42% increase from the previous year. This growth was primarily driven by the increased adoption of the TriNav system, which accounted for all the company’s revenue during the quarter. Despite this growth, the company experienced a slight decrease in gross margin, attributed to the expansion of its clean-room facilities, which was completed by early March. Cantor Fitzgerald maintained an Overweight rating on TriSalus, with a price target of $9, noting the company’s successful fundraising efforts and business outlook.
TriSalus also raised $22 million through a private placement, expected to strengthen its financial position. The company plans to use these funds to expand its commercial resources and explore new clinical applications. TriSalus anticipates a 50% revenue growth in 2025, driven by new product launches and market expansion. Additionally, the company reported a significant reduction in operating losses and expects gross margins to improve as the year progresses. In leadership changes, TriSalus appointed David B. Patience as its new Chief Financial Officer, effective July 1, 2025, succeeding James E. Young.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.